Earnings Season Highlights

Refresh your browser for the latest updates!
A collection of noteworthy post-earnings reactions
Published on Oct 18, 2021 at 1:29 PM
Updated on Oct 18, 2021 at 4:50 PM
  • Intraday Option Activity
  • Most Active Options Update
 
Published on Sep 14, 2017 at 4:09 PM
Updated on Oct 18, 2021 at 2:53 PM
  • VIX and Volatility
  • Strategies and Concepts

While earnings season is over, it won't be long before it comes around again. During this break in the action, it's a good time to review some basics about how implied volatility (IV) impacts option prices. IV plays a key role in determining the price you pay to buy an option, so it's critical to keep entry costs at a minimum in order to take full advantage of the leverage provided by options. To pinpoint stocks with attractively priced options, we've developed two proprietary volatility-based indicators: Schaeffer's Volatility Index (SVI) and Schaeffer's Volatility Scorecard (SVS).

Finding Cheap Short-Term Options with SVI
The Schaeffer's Volatility Index (SVI) is the average at-the-money (ATM) implied volatility of a stock's front-month options. The indicator is helpful to determine whether short-term options are currently pricing in high or low volatility expectations, relative to the past year's worth of data.

SVI is calculated by averaging the IV of four different options -- two calls and two puts, both in the front-month series (until the week prior to expiration, when it rolls to the next available month). Two strike prices are used; the strikes immediately above and below the stock price. The resulting average IV reading is the SVI, which is then assigned an annual percentile rank (with 0% being the lowest, and 100% the highest).

The higher the SVI percentile, the higher short-term volatility expectations are at the moment. Thus, options traders should ideally target stocks with low SVI percentile rankings, because this means near-term options are pricing in relatively low volatility expectations. Given that volatility tends to spike as known events approach, equity SVIs are usually highest prior to earnings releases.

By avoiding options with inflated SVI readings, and honing in on those with low SVIs, premium buyers can keep their cost of entry low, minimize the negative impact of time decay, and maximize the leverage of options.

Using SVS to Find Stocks That Defy Expectations

Unlike the forward-looking SVI, the Schaeffer's Volatility Scorecard (SVS) is a lagging indicator that measures a stock's realized volatility against the volatility expectations priced into that stock's options over the past year. The goal is to find which stocks have been the best -- and worst -- for premium buyers.

SVS is calculated by creating a hypothetical at-the-money straddle trade with a constant 21 days until expiration each trading day of the year, generating about 250 data points annually, with IVs derived from actual at-the-money options. The hypothetical straddle is assumed to be held until expiration, when it's closed out for intrinsic value. Based on these trades, the SVS accounts for three criteria: 40% is based on the average straddle return; 40% is based on the percentage of positive returns; and 20% is based on the percentage rank of the straddle IVs. These metrics are then combined into a score ranging from zero to 100.

If a stock has a high SVS, the underlying equity has tended to realize greater volatility on the charts over the past 12 months than what its options have priced in. The SVS then, unlike SVI, accounts for not just IV relative to itself, but IV relative to historical volatility (HV). 

As we work to uncover winning call and put trades for subscribers, both the SVI and SVS are critical tools we use to determine prime option-buying opportunities. To learn more about identifying options trades with appealing risk-reward setups, check out these tips, and find out how to use leverage ratios.

Published on Oct 18, 2021 at 2:06 PM
  • Quantitative Analysis

 

 
Published on Oct 18, 2021 at 1:42 PM
  • Buzz Stocks

8 of the Hottest Cannabis Stocks Right Now

by Schaeffer's Digital Content Team

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

Investor interest in the cannabis industry is growing at an explosive rate, and the leading players continue to break through legal barrier after legal barrier, especially in the United States. More than 40 U.S. states legalized recreational and/or medical marijuana by the end of 2020. Now, companies are starting to see the opportunity in cannabis cultivation, marketing, distribution, and technology.

Here is a quick roundup of major (and action-worthy!) cannabis stock news from this week:

1) Cresco Labs (NYSE:CL)

Cannabis company, Cresco Labs, dropped the news on Oct. 14 that they had executed a definitive agreement to pursue the $80 million acquisition of 100% of the outstanding equity interests in Laurel Harvest Labs, LLC. The deal is expected to be completed by the end of 2021. This strategic acquisition provides CL with additional distribution point in Pennsylvania, a new indoor cultivation facility, and lays the groundwork for further expansion of the facility.

2) Canopy Growth Corporation (NASDAQ:CGC)

One of the most well-known cannabis companies, Canopy Growth, acquired the right to buy the most well-known cannabis edibles brand, Wana Brands, when marijuana is legalized in the United States. This will come with a price tag of $297.5 million. An acquisition of Wana Brands means that CGC has signed an agreement with the companies that make up Wana Brands including Mountain High Products, LLC, Wana Wellness, LLC, and The Cima Group, LLC.
 
According to CEO of Canopy Growth Corp. David Klein, “As we establish Canopy Growth as the world’s leading cannabis company, acquiring the #1 cannabis edibles brand in North America will serve to strengthen our market position in both Canada and the United States."

3) GrowGeneration Corp (NASDAQ:GRWG)

GrowGeneration announced they will no longer be pursuing an asset purchase agreement with HGS Hydro, per a mutual decision made on Oct.13. With this announcement, GrowGeneration also made an downward adjustment its full year of 2021 revenue outlook down to $440 - $452 million from the previous $455 - $475 million. Shares of GRWG took a nearly 10% cut following the news on Wednesday.

4) Lexaria Bioscience Corp. (NASDAQ:LEXX)

Breaking news came from LEXX last week, with the announcement that its THC absorption study, THC-A21-1, revealed that its branded oral-delivery DehydraTECHTM-THC required only 15 minutes to deliver THC levels in blood plasma. This compares to an average 45-minute delivery time for comparable formulations. This is comparable to levels achieved at 45 minutes with concentration-matched controls.

According to Lexaria Bioscience CEO Chris Bunka, "The cannabis industry continues to use outdated formulations and processes that ignore the needs of modern THC users. THC users today include recreational, medicinal and pharmaceutical users, all of whom need technology that doesn't rely on harmful delivery methods such as smoking but still provides rapid onset and high bioavailability which common oral formats do not offer. Our study findings demonstrated rapid delivery, increased overall THC delivery, and higher brain tissue delivery; all of which is consistent with the wants and needs of THC customers."

5) Aurora Cannabis Inc. (NASDAQ:ACB) 

On Oct.12, ACB's leadership team announced its plans to donate $50,000 to support Alternative Land Use Services, an agriculture and biodiversity-focused charity, in areas surrounding Aurora's existing facilities. This donation will steward 50 acres of New Acre Project geared toward the restoration of wetlands and grasslands, creation of pollinator and wildlife habitats, and reforestation. According to Aurora CEO Miguel Martin, "As a proudly Canadian company, and global leader, Aurora deeply values the communities where we work and live."

6) High Tide Inc. (NASAQ:HITI)

HITI pushed out a press release on Oct. 12 to confirm Canna Cabana Inc., a wholly-owned subsidiary of High Tide, has been provincially licensed to operate in British Columbia, following due diligence approval from the British Columbia Liquor Distribution Branch. Along with this announcement, HITI granted 25,000 stock options to certain employees.

According to Raj Grover president and CEO of High Tide stated. “I am very proud of our team's perseverance over the last three years to achieve this major milestone. This approval allows us to expand into Canada's third-most populous province which, being famous for its 'BC Bud', has a long history of accepting cannabis culture and was ground zero for legalization in Canada."

7) Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB)

ANEB released exciting news last week as the United States Patent and Trademark Office issued a patent describing the usage of Anebulo's investigational drug, ANEB-001, geared toward the treatment of acute cannabinoid overdose. Anebulo Pharma has been providing groundbreaking work in an effort to develop new solutions for people suffering from acute cannabinoid intoxication and substance addiction.

According to Anebulo Pharma, "ANEB-001 is a competitive antagonist at the human CB1 receptor, good oral bioavailability and brain penetration (brain:plasma ratio of approximately 1.5). ANEB-001 has been shown to antagonize THC-induced hypolocomotion in mice, a CB1 receptor-mediated response. ANEB-001 is being developed for oral administration, reaches potentially therapeutic blood levels within 30 minutes and is believed to rapidly reverse the signs and symptoms of acute cannabinoid intoxication in as little as one hour."

8) Akerna Corp (NASDAQ:KERN)

According to Viridian Capital Advisors, its client, 365 Cannabis, has officially been sold to Akerna. KERN's acquisition plan for 365 Cannabis, the largest cannabis-compliant Microsoft ERP on the market, was announced originally on Oct. 4 and was completed on Monday, October 11. Akerna can now combines its compliance gateway and feature-rich reporting with 365 Cannabis' Microsoft ERP solution to create the cannabis sector's most complete portfolio of tax, financials, operations, reporting, and compliance systems.
Published on Oct 8, 2021 at 8:52 AM
Updated on Oct 18, 2021 at 1:38 PM
  • Buzz Stocks

This Week in Pot Stocks: Cannabis ETF Launches

by Schaeffer's Digital Content Team

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

Investor interest in the cannabis industry is growing at an explosive rate, and the leading players continue to break through legal barrier after legal barrier, especially in the United States. More than 40 U.S. states legalized recreational and/or medical marijuana by the end of 2020. Now, companies are starting to see the opportunity in cannabis cultivation, marketing, distribution, and technology.

Here is a quick roundup of major (and action-worthy!) cannabis stock news from this week:

1) ETFMG 2x Daily Inverse Alternative Harvest ETF (NYSE:MJIN)

A brand new cannabis-centric exchange traded fund, or ETF, came out for its first day of trading on the New York Stock Exchange on Wednesday, October 6. This new cannabis ETF was issued by ETF Managers Group LLC with a goal of delivering leveraged investment results of two times the inverse (or opposite) of the performance of the Prime Alternative Harvest Index, allowing investors access cannabis companies worldwide and leveraging the rapidly-accelerating legalization efforts worldwide.

2) High Tide Inc. (NASDAQ:HITI)

In the canna-company's latest press release on October 6, HITI announced its fourth inclusion in cannabis ETFs in the past 4 months. High Tide shares will be included in The Cannabis Growth ETF (BUDX) which went live a couple weeks ago. According to Raj Grover of High Tide, " The number of equity research analysts covering High Tide has doubled from two to four over the same time period, with more likely on the way. All of this demonstrates that our growth strategy and the execution of our business plan are not going unnoticed."

The cannabis brand also signed official agreement for its $12.32 million acquisition of 80% of Enigmaa Ltd, as announced on Thursday, October 7. Per the agreement, HITI has three years to completely buy out Enigmaa's remaining ownership.

3) Tilray Inc (NASDAQ:TLRY)

The r/WallStreetBets most-loved cannabis company's fiscal first-quarter revenue fell short of analysts' estimates on October 7, despite jumping 43% year-over-year thanks to strong demand for weed products following pandemic-related lockdowns. Meanwhile, Tilray's quarterly losses of 8 cents per share were in line with expectations.

4) Clever Leaves Holdings Inc. (NASDAQ:CLVR)

CLVR announced the export of 30 kg of cannabis flower from Portugal to US-based Biopharmaceutical Research Company. This marks the cannabis company's first commercial cannabis export from Portugal to the United States, solidifying both Clever Leaves' access to the U.S. medical marijuana market and Biopharmaceutical Research's international transaction capability.

5) Molson Coors Beverage Company (NYSE:TAP) and Hexo Corp (NASDAQ:HEXO)

TAP and HEXO announced on October 6 that the line of beverages under the brand name of Verywell is expanding its footprint within the US outside of its previously exclusive offering in Colorado. Verywell's product line features "non-alcohol, adaptogenic, hemp-derived CBD sparkling waters and unflavored beverage drops. All Veryvell products use broad-spectrum hemp and contain <0.3% THC, zero sugar and zero calories." Verywell products will now also be available in Alaska, Arkansas, Colorado, Connecticut, Florida, Iowa, Kentucky, New Jersey, New Mexico, New York, Ohio, Oklahoma, Oregon, Texas, Vermont, Virginia and West Virginia.

6) Flora Growth Corp. (NASDAQ:FLGC)

On October 6, FLGC signed an agreement to kick off a study of cannabinoid use for fibromyalgia and chronic pain patients, primarily focused on the United States and the United Kingdom. By running the trials in parallel in multiple locations, Flora Growth stated it expects to fast-track the longer expected trials. According to Flora Growth president and CEO, Luis Merchan, “Our team is incredibly excited to announce our entry into cannabinoid science which will help us achieve our goal of developing pharmaceutical cannabis products while working to advance global cannabinoid research and become a thought leader in the space."

7) Agrify Corporation (NASDAQ:AGFY)

AGFY announced the $50 million acquisition of both Precision Extraction Solutions and Cascade Sciences on October 4. Both of these acquisitions are of companies focused on the most attractive areas of the supply chain: extraction, post-processing, and testing equipment.

 

8) urban-gro, Inc. (NASDAQ:UGRO)

UGRO simultaneously launched a financial services division and signed a partnership agreement withcannabis-centric financing solution, XS Financial. According to Bradley Nattrass of urban-gro, "In response to our client’s request to provide financing solutions, I am excited to launch our new Financial Services division, and our strategic alliance with XS Financial further strengthens our purchasing power with leading horticulture manufacturers and allows us to continue to exceed client’s expectations."

9) Akerna Corp. (NASDAQ:KERN)

KERN, the leading software company in the marijuana industry, acquired 365 Cannabis at a price tag of $17 million on Monday, October 4. Through this acquisition, Akerna is now able to offer a Microsoft ERP that is cannabis compliant covering a huge number of aspects of the cannabis market including cultivation, production, compliance, distribution, and more.
 
On Tuesday, October 5, Akerna signed a securities purchase agreement for a $20 million convertible debt financing with existing institutional investors who hold the cannabis company's currently outstanding convertible notes. The purpose of this agreement is to secure capital needed for ongoing growth initiatives and is expected to produce approximately $14.6 million
 

10) Canopy Growth Corporation (NASDAQ:CGC)

CGC announced a partnership with Karma Water with plans to launch Karma CBD water, a new brand line of CBD beverages. According to Tara Rozalowsky of Canopy Growth, "This collaboration pairs Canopy Growth’s best in class CBD distillate with Karma’s innovative push cap technology, instantly infusing cannabinoids into pristine water and guarding against the natural deterioration that occurs in shelf-stable pre-mixed beverages."
Published on Oct 18, 2021 at 1:31 PM
  • Earnings Preview
 
Published on Oct 18, 2021 at 11:56 AM
  • Buzz Stocks

It has been a rocky year for Amicus Therapeutics, Inc. (NASDAQ:FOLD), after the stock suffered a dramatic bear gap back in February that it hasn't even come close to recovering from. In recent months, the equity has come up against pressure at the $12 mark, which has kept it at a 52.4% deficit for the year. FOLD is down 1.4% at $10.92 at last check, and has just pulled back to a historically bullish trendline that could have the equity making another attempt at the aforementioned $12 level. 

The trendline in question is FOLD's 40-day moving average. Data from Schaeffer's Senior Quantitative Analyst Rocky White shows the equity coming within one standard deviation of this moving average after some time above it. Similar moves have occurred seven other times in the past three years. One month after each of these signals, Amicus Therapeutics stock was higher 50% of the time, averaging a 5.2% return during that time frame. A similar move from the stock's current perch would put FOLD at $11.48, back within striking distance of that $12 ceiling. 

fold oct 18th

Amicus Therapeutics is only a couple weeks away from its earnings call, which is due out before the open on Wednesday, Nov. 3. Looking back at its last eight reports, the equity hasn't made any outsized post-earnings moves, averaging a next-day swing of just 3%, regardless of direction. Over these past eight reports, FOLD saw positive next-day returns 37.5% of the time 

Short interest, meanwhile, has been on the decline, dropping 3.7% in the last two reporting periods. The 26.88 million shares sold short still make up 11.1% of the stock's available float, however, and it would take over 13 days to buy back these bearish bets, at FOLD's average daily pace of trading. Should short interest continue to unwind, the shares could surge higher still.

Analysts are split on the equity. Of the 11 in coverage, six say "strong buy," and five say "hold." Meanwhile, the 12-month consensus price target of $16.89 is a 54.4% premium to current levels. 

Now looks like an advantageous time to speculate on FOLD's next move with options. The security's Schaeffer's Volatility Index (SVI) of 51% stands higher than just 4% of readings from the past 12 months. This means options traders are pricing in relatively low volatility expectations at the moment. 

Published on Oct 18, 2021 at 10:05 AM
Updated on Oct 18, 2021 at 11:36 AM
  • Buzz Stocks
 
Published on Oct 18, 2021 at 11:19 AM
  • Buzz Stocks
The stock's typically quiet options pits are bustling with activity this morning. Options volume is running at 12 times what is typically seen at this point, with 2,813 calls and 922 puts across the tape so far. The November 15 call is most popular, followed by the 12.50 put in the same monthly series, with new positions currently being opened at both.
Published on Oct 18, 2021 at 11:13 AM
  • Analyst Update
Drilling down to today's options activity, 40,000 cals and 25,000 puts have crossed the tape, which is double the intraday average. Most popular is the weekly 10/22 175-strike call, followed by the 180-strike call in the same series, with positions being opened at the first.
Published on Oct 18, 2021 at 9:22 AM
Updated on Oct 18, 2021 at 10:49 AM
  • Buzz Stocks

The shares of NetApp Inc. (NASDAQ:NTAP) are down 3.6% at $91.01 this morning, following a downgrade from Goldman Sachs. The analyst lowered its rating on NTAP to "sell" from "neutral," and slashed its price target to $81 from $85, citing the upcoming 2022 spending environment. 

This downgrade may come as a surprise to some, considering NetApp stock just hit a record high of $94.69, and has been charging up the charts for most of 2021. In fact, NTAP has added 42.5% this year, and has doubled in the past 12 month, while several channels of support still sit just below, including the 40-day moving average, which captured two pullbacks earlier this month, 

The majority of analysts in coverage are optimistic on NTAP, with nine of the 16 considering it a "buy" or better, heading into today. The remaining seven considered the stock a "hold." Meanwhile, the 12-month consensus price target of $95.32 is a slim 1.3% premium to last night's close. 

Options traders have also taken an optimistic stance. The equity's Schaeffer's put/call open interest ratio (SOIR) stands higher than just 1% of reading from the past year. This means short-term options traders have rarely been more put-biased. 

That being said, now could be a good time to speculate on NetApp stock's next move with options. The security's Schaeffer's Volatility Index (SVI) of 24% stands higher than just 12% of readings from the past year. This implies options traders are pricing in relatively low volatility expectations at the moment. 

Published on Oct 18, 2021 at 10:45 AM
  • Buzz Stocks

The shares of FuelCell Energy Inc (NASDAQ:FCEL) are popping this morning, last seen up 12.2% at $8.29. It's unclear what's driving the equity up the charts this early on, though there's a lot of online chatter surrounding the speculative trader target. FuelCell stock was at the forefront of the meme stock craze, preceding the uptick in interest of GameStop (GME) amongst Reddit's WallStreetBets crowd, and it looks like some well-known accounts on Twitter are drumming up interest once again.

A far cry from its Feb. 10 all-time high of $29.43, as the stock has been consolidating below the $8 level since July. The security looks ready to topple this area today, however. Plus, FCEL is pacing for its first close above its 120-day moving average since April. Year-over-year FCEL boasts a 271.4% lead.

As is typical with these meme stocks, short interest is an area of particular interest. It has been on the rise over the last month, up 10%, and the 52.88 million shares sold short now make up a healthy 15% of the stock's available float. In simpler terms, it would take these traders just over two days to buy back their bearish bets, at the equity's average pace of trading. 

Options bulls are targeting FCEL today, too. Already, 207,000 calls have crossed the tape, which is 11 times what's typically seen at this point, compared to the 23,000 puts exchanged so far. The three most popular contracts, the weekly 10/22 8-, 9-, and 8.50-strike calls all have new positions being bought to open at each. 

That bullish sentiment is nothing new, given that options traders have been call-heavy on the equity over the last two weeks. This is per the security's 10-day call/put volume ratio of 9.74 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which sits higher than 92% of readings from the past year.  

Now could be a good opportunity to take advantage of FCEL's next move with options. The stock's Schaeffer's Volatility Index (SVI) of 91% sits in the 7th percentile of its annual range, indicating that options traders are pricing in relatively low volatility expectations at the moment. Plus, the stock's Schaeffer's Volatility Scorecard (SVS) comes in at 99 (out of 100). In other words, the security has exceeded options traders' volatility expectations in the last year.

 

Begin the New Year With Schaeffer's 7 FREE 2022 Stock Picks!

1640638248

 


MORE | MARKETstories


C3.ai Stock Sells Off After Dismal Prelminary Results
AI is heading for its worst day on record after preliminary earnings and revenue fell short
Nasdaq, S&P 500 Look to Win Turbulent Week With Records
Tariff fatigue couldn't stop weekly wins for all three major indexes